Senior-level professionals and those working in the following areas of oligonucleotide science:

• Biotechnology
• Clinical Pharmacology
• Clinical Research
• Chemistry, Manufacturing, and Control
• Clinical, Regulatory, and Business Development
• Delivery Technologies
• Drug Discovery
• Preclinical
• Quality Assurance
• RNAi
• Vaccines
  

At the conclusion of this Conference, participants should be able to:

• Identify accomplishments and challenges in the clinical development of oligonucleotide-based therapeutic drugs
• Describe the critical issues in the nonclinical development of oligonucleotides
• Differentiate the chemistry, manufacturing, and controls challenges associated with the development of synthetic oligonucleotides, including formulation and specification issues
• Explain unique aspects and various scientific approaches used during the development of oligonucleotide-based therapeutics
• Recognize the achievements made in the field to date and be able to share the vision with patients about the therapeutic potential that oligonucleotides possess across a wide range of indications
• Discuss industry and regulatory agency efforts to partner and address the unmet medical needs of patients